Receive The Newest Study Notifications

- Chinese registrational clinical trial for derazantinib to begin in 2H 2019 Sinovant Sciences today announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products...

-Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019- -Oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy- BASEL, Switzerland, April 30, 2019 (GLOBE NEWSWIRE) -- Axovant Gene...

Company expects to initiate Phase 1 / 2 study 'Unite-CNM' in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and  orphan disorders, today announced that The Medicines and Healthcare products Regulatory...

Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for LBS-008...

Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), was named the winner of the CRO Quality Award from the Association of Clinical Research Professionals (ACRP) and The Avoca Groupduring the recent ACRP annual...

hRPC Cell Therapy Demonstrates Sustained and Further Improvement in Vision at 60 and 120 Days in First Cohort of Phase 2a study in Retinitis Pigmentosa Mean Change from Baseline in Visual Acuity of +23 Letters to Date LONDON, April 26, 2019 /PRNewswire/ -- ReNeuron...

The WINTHER trial***, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal...

Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, announced today that the...

At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), today presented an update...

Data from a Prospectively Designed Independent Trial of 130 Patients showed that PyL upstaged and downstaged disease in 65.5% of patients  Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence...

The WVU Cancer Institute is recruiting participants for an immunotherapy clinical trial for patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma. The trial will evaluate the effectiveness of the immunotherapy drug SD-101...

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the enrollment in its Phase 2a PRINCE (PRovention Investigation in Crohn's DiseasE)...

Scientists could help match cancer patients with no other treatment options to clinical trials with experimental medicines, by analysing the genetic faults in a sample of their blood, according to research published in Nature Medicine*. The researchers, funded by...

Leveraging innovative processes and technology to help tackle the industry’s toughest data challenges According to Tufts Center for the Study of Drug Development, the average time to build and release a clinical study database is more than 73 days and the average time...

 Clinical trials in oncology may benefit from relying on personalized combination therapies rather than matching patients to monotherapies, according to a new analysis from the Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy...

Vineti Inc., the leading software platform of record for personalized therapeutics, today announced a new partnership to advance and scale Marker Therapeutics’ T cell therapy pipeline. Marker Therapeutics is a clinical-stage immuno-oncology company specializing in the...

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License...

AEGEA Medical announced today that it has completed enrollment in the Post-Ablation Cavity Evaluation Mexico (PACE MX) clinical study of women who previously underwent endometrial ablation as part of a pivotal trial of AEGEA’s Mara™ Water Vapor Ablation Treatment. The...

  The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA) Saskatchewan is the second province after the province of Quebec to grant broad access...

€4 million extension to 2017 financing agreement BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to extend the 2017 financing agreement with BiondVax by an additional €4 million....